Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 3/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3427659 | 0.99 | KMT2A (0.51) | KMT2AFABP5FABP7POLBTDP1 | |
| SCHEMBL14237194 | 0.99 | KMT2A (0.51) | KMT2AFABP5FABP7POLBTDP1 | |
| SCHEMBL7705059 | 0.99 | KMT2A (0.51) | KMT2AFABP5FABP7POLBTDP1 | |
| SCHEMBL16598273 | 0.96 | KMT2A (0.47) | KMT2AFABP5FABP7POLBTDP1 | |
| SCHEMBL6426462 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL8332721 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL16678782 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL17110562 | 0.86 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL22095619 | 0.86 | KMT2A (0.47) | KMT2AFABP5FABP7POLBTDP1 | |
| SCHEMBL6369931 | 0.86 | KMT2A (0.47) | KMT2AFABP5FABP7POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516145-B2 | Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization | NORTHWESTERN UNIVERSITY (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4574166-A2 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN Pharmaceutica NV (BE) | 2025-06-25 | — | — | EP | disclosed |
| EP-3988123-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-26 | — | — | EP | disclosed |
| CN-118085061-A | Cyclic peptide tyrosine compounds as neuropeptide y receptor modulators | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-110099692-B | Cyclic peptide tyrosine compounds as neuropeptide y receptor modulators | 詹森药业有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-22 | — | — | US | disclosed |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| US-20100233743-A1 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | UNIVERSITY OF TARTU (EE) | 2010-09-16 | — | — | US | disclosed |
| EP-2057279-A2 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | University of Tartu (EE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008019696-A2 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | UNIVERSITY OF TARTU (EE) | 2008-02-21 | — | — | WO | disclosed |
| EP-0967205-B1 | Labeling reactants and their use | WALLAC OY (FI) | 2003-09-17 | — | — | EP | disclosed |
| CN-1379786-A | Modified peptides and peptidomimetics for use in immunotherapy | AKZO NOBEL NV (NL) | 2002-11-13 | — | — | CN | disclosed |
| EP-1226167-A1 | MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY | Akzo Nobel N.V. (NL) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001029081-A1 | MODIFIED PEPTIDES AND PEPTIDOMIMETICS FOR USE IN IMMUNOTHERAPY | AKZO NOBEL N.V. (NL) | 2001-04-26 | — | — | WO | disclosed |
| EP-0967205-A1 | Labeling reactants and their use | WALLAC OY (FI) | 1999-12-29 | — | — | EP | disclosed |
| EP-0710244-A1 | IMMUNOREACTIVE REAGENTS EMPLOYING MONOAMINE OXIDASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-08 | — | — | EP | disclosed |
| WO-1994029333-A1 | IMMUNOREACTIVE REAGENTS EMPLOYING MONOAMINE OXIDASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | KMT2A 2517/4885FABP5 639/4885FABP7 867/4885 |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | KMT2A 2517/4885FABP5 639/4885FABP7 867/4885 |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | KMT2A 2481/4885FABP5 2236/4885FABP7 2292/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | KMT2A 2481/4885FABP5 2236/4885FABP7 2292/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | KMT2A 2481/4885FABP5 2236/4885FABP7 2292/4885 |
| US-20100233743-A1 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | ADK, PRKCH, DMPK | KMT2A 2009/4885FABP5 3400/4885FABP7 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.